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Abstract
Introduction: The aim of this study was to estimate the prevalence and determinants of vitamin D deficiency in
patients with rheumatoid arthritis (RA) as compared to healthy controls and to analyze the association between
25-hydroxyvitamin D (25(OH)D) with disease activity and disability.
Methods: The study includes 1,191 consecutive RA patients (85% women) and 1,019 controls, not on vitamin D
supplements, from 22 Italian rheumatology centres. Together with parameters of disease activity, functional
impairment, and mean sun exposure time, all patients had serum 25(OH)D measured in a centralized laboratory.
Results: A total of 55% of RA patients were not taking vitamin D supplements; the proportion of these with
vitamin D deficiency (25(OH)D level <20 ng/ml) was 52%. This proportion was similar to that observed in control
subjects (58.7%). One third of supplemented patients were still vitamin D deficient. In non-supplemented RA
patients 25(OH)D levels were negatively correlated with the Health Assessment Questionnaire Disability Index,
Disease Activity Score (DAS28), and Mobility Activities of daily living score. Significantly lower 25(OH)D values were
found in patients not in disease remission or responding poorly to treatment, and with the highest Steinbrocker
functional state. Body mass index (BMI) and sun exposure time were good predictors of 25(OH)D values (P <
0.001). The association between disease activity or functional scores and 25(OH)D levels remained statistically
significant even after adjusting 25(OH)D levels for both BMI and sun exposure time.
Conclusions: In RA patients vitamin D deficiency is quite common, but similar to that found in control subjects;
disease activity and disability scores are inversely related to 25(OH)D levels.
Introduction
Vitamin D deficiency is extremely common in Europe
and particularly in Southern countries where more than
90% of elderly people are affected [1-5]. Vitamin D defi-
ciency is also frequent among young subjects: 25-hydro-
xyvitamin D (25(OH)D) levels lower than 20 ng/ml have
recently been reported in Italy in almost a third of
apparently healthy women [6].
Emerging evidence suggests that vitamin D plays an
important role in immune regulation. Vitamin D recep-
tors are found on several immune cells and in vitro
studies have shown that vitamin D metabolites modulate
T cell proliferation and dendritic cell function [7,8]. Epi-
demiological data also imply that vitamin D deficiency
may be a risk for development of autoimmune and
other chronic diseases [3,9].
Preliminary studies suggest that low levels of vitamin
D may be common in rheumatoid arthritis (RA) [10-13].
More recently, vitamin D deficiency was found in 42
out of 145 postmenopausal women with RA in the USA,
with the highest prevalence among African Americans
[14,15]. Moreover, some authors reported an inverse
relationship between serum levels of vitamin D metabo-
lites and disease activity or disability in patients with RA
or early inflammatory polyarthritis, although conflicting
results have been found [12,15-17]
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The aim of this study was to estimate the prevalence
and determinants of vitamin D deficiency in patients
with RA, and to analyze the association of vitamin D
with disease activity and disability. We hypothesized
that low levels of vitamin D would be common in




The study population includes 1,191 consecutive
patients (1,014 women, 177 men) from 22 rheumatology
centres uniformly distributed across Italy (six northern,
eight central, eight southern Italy).
The control group resulted from the merging of two
population-based studies, representative of the general
population recruited from osteoporosis centres equally
distributed over the national territory of Italy. The first
study included 700 Caucasian postmenopausal women
aged 60 to 80 years not affected by diseases or on
treatment expected to alter mineral metabolism [18].
The second study was made up of 608 premenopausal
healthy women aged 20 to 50 years [6]. The character-
istics of these two populations were described in
details elsewhere and the data analyzed by the same
coordinating centre. The aim of both studies was to
investigate the prevalence, determinants and conse-
quences of vitamin D deficiency in healthy Italian
women [6,18].
Clinical evaluation
All RA patients fulfilled the 1987 American College of
Rheumatology (ACR) revised criteria for RA. The only
inclusion criteria were a diagnosis of established RA and
an age less than 75 years, irrespective of menopausal
status. All patients were interviewed and examined at
each clinical centre for the gathering of information on
disease and treatment history.
Disease-related variables included disease onset and
duration, presence of extra-articular manifestations, 28
tender joint count (TJC28) and 28 swollen joint count
(SJC28). The three-variable Disease Activity Score (DAS
28) was calculated using C-reactive protein (CRP) and the
Nijmegen formula: DAS28 = (0.56*sqrt(TJC28) + 0.28*sqrt
(SJC28) + 0.36*ln(CRP+1)) * 1.10 + 1.15 [19]. The ACR
criteria were considered in order to classify a patient as in
remission at the time of observation. Clinical measures of
disease related functional impairment included Health
Assessment Questionnaire Disability Index (HAQ), Stein-
brocker functional state and the mobility activities of daily
living (ADL) [20-22]. RA specific treatment were collected
and included the glucocorticoids, disease modifying anti-
rheumatic drugs (DMARDs: methotrexate, cyclosporine,
gold salts, sulfasalazine, antimalarials, and azathioprine)
and the TNFa blockers (anti-TNF). Patients were inter-
viewed regarding current use of drugs affecting bone meta-
bolism including bisphosphonates, calcium and vitamin D
supplements. Vitamin D supplements taken during the pre-
vious year were carefully evaluated and expressed as mean
daily dose. Exposure to sunlight from March to September
(sun exposure time) was quantified as <10, 10 to 20, 20 to
30 or >30 minutes daily. Body weight and height (Harpen-
der stadiometer) were assessed and the body mass index
(BMI = kg/m2) was calculated in all subjects.
Laboratory assessment
Rheumatoid factor (RF), anti Cyclic Citrullinated Peptide
(anti-CCP) and routine biochemistry were measured
locally. Individual aliquots of serum samples were col-
lected from June 2007 to May 2008 from each patient.
Four aliquots were sent on dry ice by courier to the
laboratory of the University of Verona, and kept at -70°
C until the measurement of serum intact parathyroid
hormone (PTH) and 25(OH)D using commercial ELISA
kits (IDS Co., Bolden, UK) with inter-assay coefficient of
variations ranging from 5 to 15%.
The study was in compliance with the Helsinki
Declaration and was approved by the local Ethical Com-
mittees. The University Hospital of Messina was desig-
nated as the Coordinating Center, where the study
protocol was approved on 2 February 2007. An informed
written consent was obtained from all participants.
Statistical analysis
All data management and analysis were centralized and
conducted according to a prespecified plan by one of the
centres. PTH and 25(OH)D were logarithmically trans-
formed in order to normalize their distribution. The
between subgroup differences were assessed by t-test or
analysis of variance (ANOVA); analysis of covariance
(ANCOVA) was used to adjust values for any confounding
factor. Chi-square tests were used for categorical data.
Associations between continuous variables were exam-
ined using Pearson correlation coefficients and multi-
variate linear regression. Differences were considered
significant at P < 0.05. All statistical procedures were
carried out using a computer program (SPSS version
13.0, Inc., Chicago, IL, USA).
Results
The RA sample was mostly female (85%) with a mean (±
SD) age of 58.9 ± 11.1 years and disease duration of 11.5 ±
8.7 years. The main RA-related findings by gender are
listed in Table 1, which includes also the main characteris-
tics of the control women. The disease was somewhat
more severe in women than in men. The volume of the
serum sample from 23 patients was inadequate for the
measurements with the auto-analyser.
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Six hundred and thirty-four patients (55%) were not
taking native vitamin D supplements; 16% and 27% of
patients were taking ≤440 or ≥800 units of vitamin D3
per day, respectively.
The corresponding mean values of 25(OH)D and the
proportion of patients with vitamin D deficiency with
two different cut-off values are listed in Table 2.
In patients not taking vitamin D supplements, a signif-
icant negative correlation between 25(OH)D serum
levels and age was observed (P < 0.05), and mean values
from June to December were significantly higher than
from January to May (23.5 versus 19.0 ng/ml, respec-
tively, data not shown).
Among patients not vitamin D supplemented the loga-
rithm of the 25(OH)D levels (Ln 25(OH)D) levels were
significantly correlated with logarithm of PTH, BMI,
DAS28, HAQ score and ADL (Table 3). The age and
BMI adjusted mean 25(OH)D levels were not statisti-
cally different in non-supplemented RA patients (19.7 ±
10.0 ng/ml) and control women (19.2 ± 9.9 ng/ml).
Table 4 shows 25(OH)D levels by categorical variables
in patients not vitamin D supplemented.
Significantly lower 25(OH)D values were found in
patients not experiencing disease remission or with
DAS28 >5.1 or poorly responding to treatment, and
with the highest Steinbrocker functional state. Time
Table 1 Main characteristics (means and confidence intervals or percentages) of study population by gender
RA-women (N = 1,014) RA-men (N = 177) P1 Controls (N = 1,019) P2
Mean 95% C.I. Mean 95% C.I. Mean 95% C.I.
Age (years) 58.7 58.0 to 59.4 60.0 58.4 to 61.6 n.s. 58.9 58.1 to 59.7 n.s.
BMI (kg/m2) 25.0 24.7 to 25.3 25.9 25.4 to 26.5 0.01 25.7 25.5 to 26.0 0.002
Disease duration (mo.) 138 131 to 145 138 119 to 157 n.s
Swollen joint count (range 0 to 28) 3.12 2.81 to 3.43 1.98 1.53 to 2.43 0.003
DAS 28 3.96 3.90 to 4.03 3.55 3.40 to 3.70 <0.001
HAQ score (range 0 to 3) 1.18 1.13 to 1.24 0.87 0.75 to 0.99 <0.001
ADL (range 4 to 16) 8.41 3.02 to 8.22 7.24 6.85 to 7.63 <0.001
25(OH)D (ng/ml) 24.0 23.2 to 25.0 24.7 22.9 to 26.6 n.s. 19.3 18.4 to 20.2 <0.001
PTH (pg/ml) 25.0 24.1 to 25.9 24.9 23.2 to 26.6 n.s. 33.1 31.7 to 34.3 <0.001
Pre-menopause 35.7% 33.2% ns
Sun exposure time >30 minutes 33.5% 51.4% 0.01 35% ns
Smoking 20.8% 20.3% n.s. 16.3% <0.001
Extra-articular manifestations 15.3% 13.6% n.s.
Steinbrocker Functional state >1 66.8% 58.2% n.s.
DMARDs therapy 88.0% 89.3% n.s.
Anti to TNF therapy 46.5% 39.5% n.s.
ACR Remission 22.9% 24.9% n.s.
Good treatment response 43.7% 46.9% n.s.
Osteoporosis therapy 29.6% 13.6% <0.01
Glucocorticoid therapy 86.5% 83.1% n.s.
Rheumatoid Factor positive 63.3% 66.3% n.s.
Anti CCP positive 66.3% 66.7% n.s.
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; ACR, American College of Rheumatology; ADL, activities of daily living; Anti-CCP, anti Cyclic Citrullinated Peptide;
Anti-TNF, tumor necrosis factor a blocker; BMI, body mass index; CRP, C-reactive protein; DAS 28, Disease Activity Score 28; DMARDs, disease modifying
antirheumatic drugs; HAQ, Health Assessment Questionnaire Disability Index; PTH, parathyroid hormone; RA, rheumatoid arthritis.
p1 is referred to between gender differences and p2 to between female patients and control women; n.s. = not significant.
Table 2 Mean and frequency of 25(OH)D values lower than 20 or 30 mg/ml according with ranges of vitamin D
supplementations
D3 supplementation IU/day N. 25(OH)D ng/ml mean (S.D.) 25(OH)D < 20 ng/ml (%) 25(OH)D < 30 ng/ml (%)
None 654 21.0 (10.2) 51.8% 84.4%
≤ 440 196 26.1 (12.4) 33.2% 74.5%
≥800 318 29.2 (18.5) 31.4% 63.5%
Controls 1,019 19.3 (14.3)a 65.0% a 80.6% b
a = P < 0.01 and b = P < 0.05 versus supplemented RA patients.
Abbreviations: 25(OH)D (25-hydroxyvitamin D).
All differences (both proportions and means) across the three ranges of vitamin D supplementation in RA were statistically significant.
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spent outdoors during summer months (sun exposure
score) was a good predictor of 25(OH)D levels.
Patients with the worse indices of disease activity or
disability were spending significantly less time in sun-
shine (Table 5) and were then more likely to develop a
vitamin D deficiency.
Thus, the association between disease activity or dis-
ability and 25(OH)D levels was re-examined for values
adjusted for both sun exposure time and BMI, another
strong determinant of 25(OH)D values. The results of
this re-analysis are listed in Table 6.
Even after these adjustments, most indices of disease
activity or disability remained significantly related with 25
(OH)D levels and the correlations between Ln 25(OH)D
levels and HAQ score or ADL remained significant (P =
0.002 and 0.001, respectively; results not shown).
Discussion
We have found that vitamin D deficiency (25(OH)D
values <20 ng/ml) is common in RA patients affecting
43% of the entire cohort. Our results are similar to
those reported by others in smaller sample sizes, with a
prevalence of vitamin D deficiency ranging from 30 to
63% [10-15].
In our study the proportion of patients with vitamin D
deficiency rises to 52% in patients not taking vitamin D
supplements, but it was also unacceptably high in women
on approximately 400 or 800 U vitamin D daily supple-
ments, that is, 33 and 31% respectively. These latter pro-
portions rise considerably if the threshold 25(OH)D
levels are set to 30 ng/ml, but they are very similar to
those we observed in control women representative of
the general population and this indicates that vitamin D
deficiency is, at least in Italy, a general problem.
From a careful analysis of a large number of epide-
miological studies it was recently found that the optimal
25(OH)D concentrations for bone health and extra-ske-
letal benefits are between 36 to 40 ng/ml% [23]. These
levels were achieved only by 9% of our patients (results
not shown) and this indicates that, at least in RA
patients, in order to achieve 25(OH)D levels above 38
ng/ml in more than 90% of the population, the daily
dose of vitamin D should be substantially higher than
800 U per day.
Table 3 Correlations between the natural logarithm of 25(OH)D (Ln 25(OH)D) and several continuous variables in
patients not taking vitamin D supplements
Correlation coefficients (95% C.I.) Regression Coefficients (r) P
Ln PTH pg/ml -0.076 (-0.121, -0.031) 0.114 0.031
BMI (kg/m2) -0.015 (-0.022 , -0-007) 0.135 <0.001
Swollen joints count -0.009 (-0.017, -0.002) 0.087 0.121
DAS28 -0.091 (-0.129, -0.052 0.191 <0.001
HAQ score -0.101 (-0.140, -0.062) 0.175 <0.001
ADL -0.027 (-0.038, -0.016 0.165 <0.001
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; ADL, activities of daily living; BMI, body mass index; DAS 28, Disease Activity Score 28; HAQ, Health Assessment
Questionnaire Disability Index; Ln PTH, natural logarithm of parathyroid hormone.
Table 4 Mean 25(OH)D levels and proportion of patients with 25(OH)D levels <20 ng/ml according to categorical
variables in non vitamin D supplemented patients
Categorial variable Mean Standard deviation P % with 25(OH)D <20 ng/ml P
Disease Remission No 21.7 11.3 0.008 51.6% <0.001
Yes 24.2 12.1 35.4%
DAS28 <3.1 23.1 9.9 0.008 34.1% <0.001
3.1 to 5.1 20.2 11.8 59.3%
>5.1 19.4 9.2 62.0%
Steinbrocker Functional state 1 24.3 13.0 <0.001 40.7% 0.001
>1 21.1 10.4 52.0%
Treatment Response Good 23.6 13.1 41.4% <0.001
Fair 21.5 10.0 0.010 51.2%
No 20.4 10.4 58.8%
Sun exposure time <10 minutes 20.7 10.3 0.008 50.5% 0.049
10 to 20 minutes 21.1 9.1 52.3%
20 to 30 minutes 22.3 12.1 51.4%
>30 minutes 23.9 13.0 42.5%
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; ANOVA, analysis of variance); DAS 28, Disease Activity Score 28. P-values were obtained by ANOVA and Chi square test.
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As expected, the logarithmic values of 25(OH)D were
negatively (P < 0.04) correlated with the logarithmic
levels of PTH, but only in patients not on vitamin D
supplements.
In non-supplemented patients, 25(OH)D levels were asso-
ciated with several variables. Sun exposure and BMI are
well established risk factors for vitamin D deficiency and
these associations are confirmed in the present study [24].
The scope of this study was to evaluate to what extent
vitamin D deficiency was related in RA patients with the
severity of the disease. The inverse relationships
between vitamin D levels and disease activity or func-
tional impairment are of interest but not of obvious
interpretation. Similar relationships have been found
also by others. Cutolo et al. reported a significant
inverse association between 25(OH)D and DAS28 in
patients with active RA and Patel et al. found an inverse
relationship between 25(OH)D levels and tender joint
count, DAS28, and HAQ score only at disease onset,
but not in patients with a disease duration longer than
one to two years [16,17]. Though our study population
included a large variety of disease activity, treatments
and disease durations, the correlations we found were
all highly significant and this is likely explained by the
size of our study, 6- to 10-fold larger than previous stu-
dies. We found that the worse the direct or indirect
indices of disease activity, the lower the 25(OH)D levels
or the higher the proportion of patients with vitamin D
deficiency. Thus, the proportion of patients with vitamin
D deficiency was around 30% lower in patients on dis-
ease remission or judged as good responders to treat-
ment or for a DAS28 <3.1. In addition, both functional
indices and mobility ADL were negatively associated
with 25(OH)D levels with a P < 0.001.
At a first glance, the most obvious explanation for these
findings is that patients with very active disease are at
higher risk of vitamin D deficiency rather than the other
way around. Indeed, we found an association between sun
exposure time and achievement of disease remission, good
treatment response, Steinbrocker’s functional state, HAQ
and swollen joint counts. This indicates that patients with
uncontrolled RA and/or with severe functional impair-
ment are less prone to spend time outdoors in sunshine
and are, therefore, at higher risk of vitamin D deficiency.
Thus, the conclusions drawn in previous cross-sectional
studies regarding the immunomodulatory role played by
vitamin D in inflammatory arthritis, should be interpreted
with caution, if 25(OH)D values are not adjusted for the
known risk factors for vitamin D deficiency [16,17]. How-
ever, when the correlations between disease activity scores
and vitamin D deficiency were reanalysed by adjusting the
25(OH)D levels for sun exposure and BMI, the association
remained statistically significant for Steinbrocker’s func-
tional state, DAS28, treatment response, HAQ score and
mobility ADL. These results indicate that patients with
very active RA are at higher risk of vitamin D deficiency
for similar BMI and sun exposure, for reasons that remain
unknown.
The main strength of this study is its size. There are
also important limitations. The large heterogeneity in
terms of specific treatments and disease duration ham-
pers the interpretation of some associations but it is of
help for defining the risk of developing vitamin D defi-
ciency. Our control group was identified a posteriori
and it was not perfectly matched since it does not
include men and women aged 50 to 60 years.
Table 5 Association between daily sun exposure time (minutes) and parameters of disease activity or disability
(percent of patients or mean ± SD)
Sun exposure time (minutes) <10 10 to 20 20 to 30 >30 P = Chi-square or ANOVA
Disease Remission = No 85.8% 70.3% 76.3% 73.7% 0.007
Treatment Response = Fair or No 61.1% 54.6% 50.6% 52.9% 0.05
Steinbrocker Functional state > 1 69.6% 66.5% 59.0% 57.4% 0.001
Swollen joints count 4.3 ± 6.3 3.2 ± 4.9 2.4 ± 4.0 2.1 ± 3.3 <0.001
DAS28 >3.1 83.1% 73.7% 70.9% 65.5% <0.001
HAQ score 1.4 ± 0.9 1.2 ± 0.9 1.0 ± 0.8 0.9 ± 0.7 <0.001
Abbreviations: DAS 28, Disease Activity Score 28; HAQ, Health Assessment Questionnaire Disability Index.
Table 6 Mean 25(OH)D levels adjusted for BMI and sun
exposure time according to categorical variables in non
vitamin D supplemented patients
Categorial variable Mean Standard
deviation
P




1 24.0 12.8 0.001
>1 21.2 10.1
DAS28 <3.1 22.6 9.9 <0.001
>3.1 20.3 10.7
Treatment response Good 23.4 12.1 0.020
Fair 21.5 9.9
No 20.5 10.1
Abbreviations: ANOVA, analysis of variance; 25(OH)D, 25-hydroxyvitamin D;
BMI, body mass index; DAS 28, Disease Activity Score 28. P-values were
obtained by ANOVA and Chi square test.
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Conclusions
In this study we found that in RA, patients’ vitamin D
deficiency is quite common, but not more common than
in age-matched control women representative of the gen-
eral population. 25(OH)D levels were strongly inverse
related to disease activity and disability scores. The caus-
ality of these associations remain to be assessed in longi-
tudinal studies aimed at evaluating the clinical response
to a vitamin D supplementation dose regimen large
enough to increase 25(OH)D levels over 38 ng/ml [25].
Abbreviations
25(OH)D: 25-hydroxyvitamin D; ACR: American College of Rheumatology;
ADL: activities of daily living; ANCOVA: analysis of covariance; ANOVA:
analysis of variance; Anti-CCP: anti Cyclic Citrullinated Peptide; Anti-TNF:
tumor necrosis factor a blocker; BMI: body mass index; CRP: C-reactive
protein; DAS 28: Disease Activity Score 28; DMARDs: disease modifying
antirheumatic drugs; HAQ: Health Assessment Questionnaire Disability Index;
PTH: parathyroid hormone; RA: rheumatoid arthritis; RF: rheumatoid factor;
SJC28: 28 swollen joint count; TJC28: 28 tender joint count.
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